(tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-5-iodopentanoate) | 173690-59-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-5-iodopentanoate)
• 英文别名: tert-butyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-iodopentanoate；tert-butyl (2S)-5-iodo-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate
• CAS: 173690-59-0
• 化学式: C₁₄H₂₆INO₄
• 分子量: 399.269
• InChiKey: QPPOILFAPMMPJG-JTQLQIEISA-N

物化性质

• 沸点：
  404.8±40.0 °C(Predicted)
• 密度：
  1.354±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-5-iodopentanoate) 在 二碳酸二叔丁酯 、 盐酸羟胺 、 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.75h， 生成
  参考文献：
  名称：

  Synthesis of the L-arginine congener L-Indospicine and evaluation of its interaction with nitric oxide synthase

  摘要：

  L-Indospicine (Ind), a natural product amino acid analog of L-arginine, was synthesized from L-glutamic acid 2 in nine steps and 29% overall yield. Ind was evaluated as an alternative substrate or inhibitor of two nitric oxide synthase (NOS) isozymes. Ind did not act as either an alternative substrate or inhibitor of either NOS isozyme and these results were interpreted based on a recent model for substrate and inhibitor binding to the active site of NOS.

  DOI：

  10.1016/0960-894x(95)00569-f
• 作为产物：
  描述：

  Boc-L-谷氨酸-1-叔丁酯 在 咪唑 、 sodium tetrahydroborate 、 碘 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 1.58h， 生成 (tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-5-iodopentanoate)
  参考文献：
  名称：

  硝基烷系留肽的化学选择性氧化腈-炔烃1,3-偶极环加成反应

  摘要：

  报道了具有硝基烷烃侧链的新氨基酸的合成和掺入肽，硝基烷烃侧链的原位转化为氧化亚氮以及在原位产生的氧化亚氮与不同炔烃之间的化学选择性的1,3-偶极环加成反应。发现硝基烷介导的丁腈-炔环加成与铜（I）催化的叠氮化物-炔环加成反应正交。可以探索正交的一氧化二氮-炔烃和叠氮化物-炔烃环加成反应的组合，分别在肽主链上定制不同的1,2,3-三唑和3,5-异恶唑。

  DOI：

  10.1021/acs.orglett.7b01498

文献信息

• Synthesis and Structure Activity Relationships of a Novel Antifungal Agent, Azoxybacilin.
  作者：Jun OHWADA、Isao UMEDA、Hitomi ONTSUKA、Yuhko AOKI、Nobuo SHIMMA

  DOI：10.1248/cpb.42.1703

  日期：——

  A new antifungal substance, azoxybacilin (an unusual amino acid with an azoxy moiety) and its derivatives have been synthesized from Boc-L-Asp-OtBu utilizing the Moss procedure for the preparation of the azoxy moiety. The ester derivative, Ro 09-1824, showed more potent antifungal activity and a broader antifungal spectrum than azoxybacilin did.

  一种新的抗真菌物质，阿唑氧巴西林（一种带有阿唑氧基部分的不规则氨基酸）及其衍生物已通过Moss方法从Boc-L-Asp-OtBu合成，旨在制备阿唑氧基部分。酯衍生物Ro 09-1824显示出比阿唑氧巴西林更强的抗真菌活性和更广泛的抗真菌谱。
• Dipeptide nitriles
  申请人：Novartis AG

  公开号：US06353017B1

  公开（公告）日：2002-03-05

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽腈可作为半胱氨酸蛋白酶抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗依赖于半胱氨酸蛋白酶的疾病和症状，包括炎症、类风湿关节炎、骨关节炎、骨质疏松、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉粥样硬化（包括动脉粥样硬化斑块破裂和不稳定）。特定的二肽腈化合物为公式I的化合物，或其生理上可接受和可裂解的酯或盐，其中：符号如定义。特别是发现通过适当选择基团R、R2、R3、R4、R5、X1、Y和L，可以改变化合物作为各种半胱氨酸蛋白酶类型抑制剂的相对选择性，例如半胱氨酸蛋白酶B、K、L和S，可改变，例如获得选择性抑制特定蛋白酶类型或蛋白酶类型组合的抑制剂。
• Dipeptide derivatives
  申请人：——

  公开号：US20040110806A1

  公开（公告）日：2004-06-10

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof 1 wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R 2 , R 3 , R 4 , R 5 , X 1 , Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代的二肽硝基化合物可作为半胱氨酸蛋白酶的抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗半胱氨酸蛋白酶依赖性疾病和病况，包括炎症、类风湿性关节炎、骨关节炎、骨质疏松症、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉粥样硬化（包括动脉粥样硬化斑块破裂和不稳定性）。特定的二肽硝基化合物是公式I的化合物，或其生理上可接受和可分解酯或其盐，其中：符号的定义如上所述。特别是，通过适当选择R、R2、R3、R4、R5、X1、Y和L基团，可以改变化合物作为不同半胱氨酸蛋白酶类型的抑制剂的相对选择性，例如获得选择性抑制特定半胱氨酸蛋白酶类型或半胱氨酸蛋白酶类型组合的抑制剂。
• DIPEPTIDE NITRILES
  申请人：Altmann Eva

  公开号：US20080027060A1

  公开（公告）日：2008-01-31

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R 2 , R 3 , R 4 , R 5 , X 1 , Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽基腈可作为半胱氨酸蛋白酶的抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗半胱氨酸蛋白酶依赖性疾病和病况，包括炎症、类风湿关节炎、骨关节炎、骨质疏松症、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉硬化（包括动脉粥样硬化斑块破裂和不稳定性）。特定的二肽基腈化合物为I式化合物，或其生理上可接受和可水解酯或其盐。其中：符号如定义。特别地，通过适当选择R、R2、R3、R4、R5、X1、Y和L基团，可以改变化合物作为各种半胱氨酸蛋白酶类型的抑制剂的相对选择性，例如获得选择性抑制特定半胱氨酸蛋白酶类型或半胱氨酸蛋白酶类型组合的抑制剂。
• [EN] RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN<br/>[FR] COMPOSÉS RADIOMARQUÉS CIBLANT L'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2022126275A1

  公开（公告）日：2022-06-23

  The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.

  本发明涉及放射性标记化合物，用于体内成像或治疗由前列腺特异性膜抗原表达所特征的疾病或病况。